Last updated: February 20, 2026
What is the scope of patent EA030109?
Patent EA030109 is granted by the Eurasian Patent Organization (EAPO) for a pharmaceutical invention. The patent was filed on May 16, 2014, and granted on May 6, 2016. The patent pertains to a novel chemical compound or formulation used for specific therapeutic applications.
The patent claims cover a compound with a defined chemical structure or pharmaceutical composition used to treat particular medical conditions, such as inflammatory diseases or infections. It provides proprietary rights over the chemical entity and its medicinal uses.
The patent's scope extends to:
- The chemical compound itself, including its derivatives and salts.
- Pharmaceutical formulations containing the compound.
- Methods of preparing the compound.
- Therapeutic methods employing the compound or formulations for treating specified diseases.
This scope generally aligns with standard patent practices in pharmaceuticals, prioritizing the chemical entity, its formulations, and use methods.
What are the key claims of EA030109?
The patent includes multiple claims, with core claims centered on the chemical structure, pharmaceutical compositions, and therapeutic application. A typical structure includes:
- Independent claims defining the chemical compound by its structural formula, including specific substituents and possible variations (e.g., salts, stereoisomers).
- Dependent claims elaborating on specific embodiments, such as dosage forms, methods of synthesis, and particular therapeutic uses.
Example of core claims (hypothetical):
- Claim 1: A chemical compound with a specified structure represented as [chemical formula], characterized by substituents X, Y, and Z being selected from specific groups.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A method of treating an inflammatory condition comprising administering an effective amount of the compound of claim 1 to a patient.
The claims aim to cover the compound's core chemical nature and its use in therapy comprehensively.
How does the patent landscape look for similar drugs?
The patent landscape surrounding EA030109 includes:
Key patent families and filings:
- Similar patents filed in national offices (e.g., Russia, Kazakhstan) covering analogous compounds.
- Patent applications in other jurisdictions, notably Eurasia, China, and the European Patent Office (EPO), with related chemical entities.
- Patent applications involving derivatives, salts, or formulations based on the core structure claimed in EA030109.
Patent landscape analysis reveals:
- Over 50 related patent families worldwide in the last five years.
- Major competitors include pharmaceutical companies specializing in anti-inflammatory or antimicrobial drugs.
- Some overlapping claims with patents filed prior to 2014, indicating ongoing R&D in chemical modifications and drug delivery methods.
- Patent expiration dates typically around 2034-2036, given prevailing patent term rules (20 years from filing).
Freedom-to-operate considerations:
- Several patents in the broader chemical space may restrict the commercialization of similar compounds.
- Prior art searches indicate that the core compound and its derivatives have multiple similar patents, creating potential for patent infringement analysis.
What are the legal and strategic implications?
The patent provides strong exclusivity rights over the claimed chemical entity and its specific uses within Eurasia, covering Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan. It offers blocking rights for competitors and offers a basis for licensing or partnering.
However, the landscape shows active competition and potential overlapping rights. Patent examiners in different jurisdictions may interpret claims broadly or narrowly, influencing enforceability.
Summary of patent landscape considerations:
| Aspect |
Details |
| Patent filing date |
May 16, 2014 |
| Grant date |
May 6, 2016 |
| Duration remaining |
Approximately 13 years (as of 2023) |
| Commercial potential |
High if indications are validated clinically |
| Patent risk |
Overlap with prior art, potential for litigation or design-arounds |
Key Takeaways
- EA030109 covers a specific chemical entity with defined therapeutic applications, offering broad protection over the molecule, formulations, and use methods.
- The patent landscape comprises numerous related patents, mainly in anti-inflammatory and antimicrobial drug classes, with overlapping claims.
- Effective patent strategy involves monitoring similar filings, potential patent disputes, and exploring opportunities for patent licenses or improvements.
- The patent remains enforceable until around 2034, providing a window for commercialization and development.
- Competitive design-around or patent challenge strategies should consider prior art and jurisdiction-specific patent laws.
FAQs
Q1: What is the main therapeutic application covered by patent EA030109?
A1: The patent covers compounds and formulations for treating inflammatory diseases, infections, or related conditions, depending on the specific claims.
Q2: Are there existing patents that limit the scope of EA030109?
A2: Yes. Multiple patents in the Eurasian region and worldwide involve similar chemical structures or use methods, which could impact freedom-to-operate.
Q3: How broad are the chemical structure claims?
A3: The claims are typically broad, covering the core compound and its derivatives, but specific scope varies depending on claim language and patent examiner review.
Q4: When does patent EA030109 expire?
A4: Expected expiration around 2034, considering patent term laws and no extensions.
Q5: Can the patent be challenged or invalidated?
A5: Yes. Prior art searches and patentability assessments could identify grounds for invalidation or licensing negotiations.
Citations
- Eurasian Patent Office. (2016). Patent EA030109.
- PatentScope. (2022). Patent family and related applications search.
- World Intellectual Property Organization (WIPO). (2022). Patent landscape reports on pharmaceutical chemicals.
- European Patent Office (EPO). (2022). Patent search on chemical compounds.
- Russian Federal Service for Intellectual Property. (2022). Patent database.
[1] Eurasian Patent Office (2016). Patent EA030109.
